Are breast screening recall rates associated with body mass index? Analysis of data from a population-based screening program.
1/5 보강
[BACKGROUND] Increased body mass index (BMI) is associated with increased risk of post-menopausal breast cancer, but little is known about its association with other key screening outcomes.
- p-value P=0.019
APA
Marriott R, Pirikahu S, et al. (2026). Are breast screening recall rates associated with body mass index? Analysis of data from a population-based screening program.. Obesity research & clinical practice, 20(2), 155-163. https://doi.org/10.1016/j.orcp.2026.02.003
MLA
Marriott R, et al.. "Are breast screening recall rates associated with body mass index? Analysis of data from a population-based screening program.." Obesity research & clinical practice, vol. 20, no. 2, 2026, pp. 155-163.
PMID
41741269 ↗
Abstract 한글 요약
[BACKGROUND] Increased body mass index (BMI) is associated with increased risk of post-menopausal breast cancer, but little is known about its association with other key screening outcomes. This study investigates the association between BMI and the likelihood of being recalled after routine screening mammography.
[METHODS] To describe the associations between recall rates (crude and age-standardized) and BMI, descriptive statistics were estimated from screening events from clients attending the population-based BreastScreen Western Australia program. For those recalled, multivariable logistic regression models were fitted to investigate the association between BMI and invasive breast cancer and ductal carcinoma in situ (DCIS).
[RESULTS] The probability of being recalled following mammographic screening was non-linearly associated with BMI and differed by screening round (P=0.019). Women screening for the first time had lower odds of being recalled if they had very low BMI (<18.5 kg/m) or very high BMI (>35 kg/m), compared to those with normal BMI. For women who had screened previously, the odds of being recalled were also lower for those with very low BMI. Among those recalled, women with higher BMI had higher odds of being diagnosed with invasive breast cancer, but not DCIS, relative to those with normal BMI.
[CONCLUSION] The decision to recall following mammographic screening may be influenced by prior screening information, which may help explain inconsistent non-linear associations between BMI and recall rates between first time and subsequent screeners. Once recalled, high odds of detection within women with obesity are indicative of increased specificity of mammography to detect cancers.
[METHODS] To describe the associations between recall rates (crude and age-standardized) and BMI, descriptive statistics were estimated from screening events from clients attending the population-based BreastScreen Western Australia program. For those recalled, multivariable logistic regression models were fitted to investigate the association between BMI and invasive breast cancer and ductal carcinoma in situ (DCIS).
[RESULTS] The probability of being recalled following mammographic screening was non-linearly associated with BMI and differed by screening round (P=0.019). Women screening for the first time had lower odds of being recalled if they had very low BMI (<18.5 kg/m) or very high BMI (>35 kg/m), compared to those with normal BMI. For women who had screened previously, the odds of being recalled were also lower for those with very low BMI. Among those recalled, women with higher BMI had higher odds of being diagnosed with invasive breast cancer, but not DCIS, relative to those with normal BMI.
[CONCLUSION] The decision to recall following mammographic screening may be influenced by prior screening information, which may help explain inconsistent non-linear associations between BMI and recall rates between first time and subsequent screeners. Once recalled, high odds of detection within women with obesity are indicative of increased specificity of mammography to detect cancers.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.